Erosive Esophagitis Clinical Trial
Official title:
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg Once-Daily) Compared to AG-1749 (15 mg Once-Daily) in a 24-week Maintenance Treatment in Patients With Healed Erosive Esophagitis (EE).
Verified date | August 2013 |
Source | Takeda |
Contact | n/a |
Is FDA regulated | No |
Health authority | Japan: Ministry of Health, Labor and Welfare |
Study type | Interventional |
The purpose of this study is to confirm the efficacy of TAK-438, once daily (QD), compared to lansoprazole for the maintenance treatment of healed erosive esophagitis and to determine the clinical dose.
Status | Completed |
Enrollment | 607 |
Est. completion date | March 2013 |
Est. primary completion date | March 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: 1. At Visit H-1 (start of the treatment period), the participants must have endoscopically confirmed erosive esophagitis of Grade A to D, as defined by the LA classification grading system, and the target number of participants who are clearly Grade C or D is 15% or more of the total participants. 2. Outpatients (including inpatient for examination) 3. Participants must have successfully completed the treatment period and have endoscopically healed EE at Week 2, 4, or 8 in the treatment period. Endoscopically healed EE is defined as those participants who have endoscopically confirmed EE of Grade O as defined by the LA classification grading system. Exclusion Criteria: 1. Participants with an esophagus-related complication (eosinophilic esophagitis, esophageal varices, scleroderma, viral or fungal infection, esophageal stenosis, etc.), a history of radiotherapy or cryotherapy of the esophagus, a caustic or physiochemical trauma (esophageal sclerotherapy, etc.). However, participants with Schatzki's ring (mucosal tissue ring around inferior esophageal sphincter) or Barrett's esophagus are allowed to be included. 2. Participants who have received surgery or treatment affecting gastroesophageal reflux (cardioplasty, dilation of esophageal stenosis [excluding Schatzki's ring], etc.), or who have a history of surgery of stomach or duodenum (excluding removal of benign polyp under endoscopy) 3. Participants who have acute upper gastrointestinal bleeding, gastric or duodenal ulcer (mucosal defect with white coating) within 30 days prior to Visit H-1 (initiation of study drug administration). However, participants with gastric or duodenal erosions are allowed to be included. 4. Participants with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorder |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Takeda |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Endoscopically confirmed recurrence rate of erosive esophagitis after 24 weeks of maintenance treatment | Endoscopic recurrence of erosive esophagitis is defined as those participants who have endoscopically confirmed EE of Grade A to D as defined by the Los Angeles (LA) Classification Grading System. The definitions of each grade are: Grade O (No mucosal break), Grade A (Mucosal break <5 mm), Grade B (Mucosal break =5 mm), Grade C (Mucosal break continuous between two or more folds and <75% of the circumference) and Grade D (Mucosal break =75% of the circumference). | 24 Weeks. | No |
Secondary | Endoscopically confirmed recurrence rate of erosive esophagitis after 12 weeks of maintenance treatment | 12 Weeks. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01452776 -
Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis
|
Phase 3 | |
Recruiting |
NCT05587309 -
A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis
|
Phase 3 | |
Completed |
NCT04124926 -
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis
|
Phase 3 | |
Completed |
NCT00228527 -
Esomeprazole for Treatment of GERD in Pediatric Patients
|
Phase 4 | |
Completed |
NCT01499368 -
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients
|
Phase 3 | |
Not yet recruiting |
NCT04613895 -
Treatment Effect According to Timing of Administration of DWP14012 40 mg
|
N/A | |
Recruiting |
NCT02615184 -
A Study of Dexlansoprazole in Healing and Maintenance of Healed Erosive Esophagitis (EE) in Children
|
Phase 2 | |
Completed |
NCT02456935 -
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis
|
Phase 3 | |
Completed |
NCT02028663 -
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis
|
Phase 2 | |
Completed |
NCT03006874 -
Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis
|
Phase 3 | |
Completed |
NCT02388724 -
Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis
|
Phase 3 | |
Completed |
NCT01865825 -
Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?
|
N/A | |
Completed |
NCT02679508 -
Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety
|
Phase 4 | |
Recruiting |
NCT06391177 -
A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily
|
Phase 1 | |
Completed |
NCT05050188 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008
|
Phase 1 | |
Completed |
NCT01874535 -
Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy
|
Phase 4 | |
Completed |
NCT00206180 -
NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis
|
Phase 4 | |
Completed |
NCT01642615 -
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
|
Phase 2 | |
Completed |
NCT01630746 -
A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis
|
Phase 3 | |
Completed |
NCT01509261 -
Efficacy Study of Ilaprazole to Treat Erosive Esophgitis
|
Phase 3 |